Article type
Abstract
Background: Olanzapine is an antipsychotic drug that helps to improve the symptoms of schizophrenia, however, may cause weight gain. A Cochrane review conducted in 2005 assessed the clinical effects and safety of olanzapine compared with placebo for people with schizophrenia.
Objectives: This review aims to update the recent evidence of this review.
Methods: On 10 February 2021, we searched the Cochrane Schizophrenia Group's Study-Based Register of Trials which is based on CENTRAL, CINAHL, ClinicalTrials.Gov, Embase, ISRCTN, MEDLINE, PsycINFO, PubMed, and WHO ICTRP. All randomized controlled trials (RCTs) comparing olanzapine with placebo for people with schizophrenia.
Results: In the 2005 review, result showed that olanzapine appeared superior to placebo for the outcome of 'no important clinical response' (2 RCTs with 418 participants) but may lead to weight gain. Whether olanzapine increased dizziness and dry mouth remained uncertain due to imprecision result. This update review included 34 RCTs with 10512 participants. Data confirmed that olanzapine (any form) had a higher responder rate for improvement in global state (RR 1.78, 95% CI 1.29 to 2.44; participants = 1175; studies = 5) and general mental state (RR 1.78, 95% CI 1.38 to 2.29; participants = 1810; studies = 9). Data also indicated participants who received olanzapine showed higher incidence of weight increase (RR 3.18, 95% CI 1.74 to 5.80; participants = 2015; studies = 9). With more data included, meta-analyses showed clear result that olanzapine increased risk of dizziness (RR 2.95, 95% CI 1.34 to 6.46; participants = 1095; studies = 6) and dry mouth (RR 4.43, 95% CI 2.17 to 9.02; participants = 2052; studies = 8).
Conclusion: Olanzapine achieves better clinical response in global state and mental state but may increase risk of weight gain, dizziness and dry mouth.
Objectives: This review aims to update the recent evidence of this review.
Methods: On 10 February 2021, we searched the Cochrane Schizophrenia Group's Study-Based Register of Trials which is based on CENTRAL, CINAHL, ClinicalTrials.Gov, Embase, ISRCTN, MEDLINE, PsycINFO, PubMed, and WHO ICTRP. All randomized controlled trials (RCTs) comparing olanzapine with placebo for people with schizophrenia.
Results: In the 2005 review, result showed that olanzapine appeared superior to placebo for the outcome of 'no important clinical response' (2 RCTs with 418 participants) but may lead to weight gain. Whether olanzapine increased dizziness and dry mouth remained uncertain due to imprecision result. This update review included 34 RCTs with 10512 participants. Data confirmed that olanzapine (any form) had a higher responder rate for improvement in global state (RR 1.78, 95% CI 1.29 to 2.44; participants = 1175; studies = 5) and general mental state (RR 1.78, 95% CI 1.38 to 2.29; participants = 1810; studies = 9). Data also indicated participants who received olanzapine showed higher incidence of weight increase (RR 3.18, 95% CI 1.74 to 5.80; participants = 2015; studies = 9). With more data included, meta-analyses showed clear result that olanzapine increased risk of dizziness (RR 2.95, 95% CI 1.34 to 6.46; participants = 1095; studies = 6) and dry mouth (RR 4.43, 95% CI 2.17 to 9.02; participants = 2052; studies = 8).
Conclusion: Olanzapine achieves better clinical response in global state and mental state but may increase risk of weight gain, dizziness and dry mouth.